GlassScriptPhysician profile
James D Amlicke
NPI 1508961996
$5,294.08
in general payments reported to CMS, 2019-2025
27 companies · $497 in 2025
The $497 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $541 · 2021: $322 · 2022: $658 · 2023: $826 · 2024: $1,326 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,524 · Travel and Lodging: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,523.90 |
| Travel and Lodging | $125.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $697.29 | 2019-2025 | Avvigo Guidance System, Watchman Flx |
| Amgen INC. | $469.29 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $442.29 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $425.17 | 2019-2025 | |
| Abbott Laboratories | $352.29 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $328.03 | 2019-2025 | Eliquis, Camzyos |
| Inari Medical, INC. | $306.15 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boehringer Ingelheim Pharmaceuticals, INC. | $305.32 | 2019-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $256.02 | 2019-2023 | Uptravi, Opsumit |
| Penumbra, INC. | $245.19 | 2024 | Indigo System |
| Shockwave Medical, INC | $244.22 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Teleflex LLC | $226.89 | 2023-2024 | Trapliner, Manta |
| Astrazeneca Pharmaceuticals LP | $215.74 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $162.46 | 2019 | |
| Merck Sharp & Dohme LLC | $115.63 | 2022-2025 | Verquvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $115.26 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $109.82 | 2019 | |
| Pfizer INC. | $89.06 | 2019-2024 | |
| Acist Medical Systems, INC. | $41.09 | 2022-2024 | |
| Esperion Therapeutics, INC. | $23.61 | 2020 | |
| Philips North America LLC | $21.11 | 2025 | Extended Holter |
| Bayer Healthcare Pharmaceuticals INC. | $19.65 | 2019 | |
| Daiichi Sankyo INC. | $19.60 | 2020 | |
| Celonova Biosciences, INC. | $16.85 | 2019 | |
| Scpharmaceuticals INC. | $15.66 | 2024 | |
| Recor Medical INC | $15.20 | 2024 | Paradise Renal Denervation System |
| Abiomed | $15.19 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Amlicke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.